Both studies are both about the same idea, safely doing less surgery for breast cancer patients when they don’t need it. More and more women now receive neoadjuvant therapy. It shrinks the tumour and that changes how we should operate, both on the breast and in the axilla. Well, neoadjudant therapy lets many women keep their breasts instead of having a mastectomy, But surgeons Patients have worried that after this treatment, the margins are harder to get right, so more patients might get more than a second operation...
Both studies are both about the same idea, safely doing less surgery for breast cancer patients when they don’t need it. More and more women now receive neoadjuvant therapy. It shrinks the tumour and that changes how we should operate, both on the breast and in the axilla. Well, neoadjudant therapy lets many women keep their breasts instead of having a mastectomy, But surgeons Patients have worried that after this treatment, the margins are harder to get right, so more patients might get more than a second operation. in experience, no. We studied more than 1 ,000 patients who had breast cancer surgery at Clinica Universidad de Navarra. The neoadjuvant patients had larger, more aggressive tumours, and even so, their accretion rates were the same, 9 .6 % with upfront surgery and 8 .9 % after neoadjudant therapy. Well, the tumour itself, specifically when it’s multifocal or multicentric. That was the only dependent factor with almost three times the risk of a second surgery. So the message for surgeons is that neoadjuvant therapy is not the problem. Multifocal and multicentric disease is where we need to plan most carefully. After adjusting for confounding factors, such as tumour size, subtype and nodal sediments, we found no differences in recurrence or offline survival between the two groups. Local-regional recurrence was about 2 .5 % in both. I should be CLEAR, though, that our mean follow-up is only 30 months, so we need longer follow-ups to CONFIRM this.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.